Crossfire Oncology

Crossfire Oncology is a private, preclinical-stage biotech developing a next-generation portfolio of kinase-targeting therapies through its proprietary EPriL (Energetically Privileged Ligands) platform. The company's strategy involves selecting from three distinct modalities—inhibitors, degraders, and Degrader Antibody Conjugates (DACs)—to optimally match the biological profile of each kinase target, aiming for improved efficacy and reduced toxicity. Its most advanced internal program, CFON-026, is a non-covalent BTK inhibitor planned to enter clinical trials in the second half of 2025. The team comprises seasoned veterans in medicinal chemistry with a track record of designing drugs that have advanced into clinical development.

Proprietary EPriL (Energetically Privileged Ligands) chemistry platform enabling the design of three therapeutic modalities: non-covalent kinase inhibitors with long residence time, heterobifunctional degraders (PROTACs), and Degrader Antibody Conjugates (DACs). The platform selects the modality based on the target kinase's biology.

Crossfire competes in the crowded kinase inhibitor space against pharma giants and biotechs. In non-covalent BTK, it faces competition from approved (pirtobrutinib) and clinical-stage agents. In degradation/DACs, it competes with dedicated TPD companies (e.g., Arvinas, Kymera) and large pharma ADC leaders, though its EPriL chemistry offers a potential point of differentiation.